Association between Functional Small Airway Disease and FEV1 Decline in Chronic Obstructive Pulmonary Disease. by Bhatt, SP et al.
	



	
				
					
	

	
				
 !

∀		#∃%#∃
#&#∋#&	()∗+
	
,(!− ,.
	
/	
	
+0123 4%5.+6


	
04	47# (!, 89: 9;∃∃< −8):&
		

∋ −  +!− ∗  :!! 4
=!− /0	.+
∃
	0	




/.+6

	
04	47


		/>:∋
0
		
	 		
	?	

				

1Association between functional small airways disease and FEV1 decline in COPD
Į
Surya P. Bhatt, M.D.,
1,2 Į
Xavier Soler, M.D., Ph.D.,
3
Xin Wang, M.S.,
4
Susan Murray, Sc.D.,
4
Antonio R. Anzueto, M.D.,
5
Terri H. Beaty, Ph.D.,
6
Aladin M. Boriek, Ph.D.,
7
Richard Casaburi,
Ph.D., M.D.,
8
Gerard J. Criner, M.D.,
9
Alejandro A. Diaz, M.D., M.P.H.,
10
Mark T. Dransfield,
M.D.,
1,2
Douglas Curran-Everett, Ph.D.,
11,12
Craig J. Galbán, Ph.D.,
13
Eric A. Hoffman,Ph.D.,
14
James C. Hogg, M.D., Ph.D.,
15
Ella A. Kazerooni,M.D.,
16
Victor Kim,M.D.,
9
Gregory L Kinney,
Ph.D.,
17
Amir Lagstein, M.D.,
18
David A. Lynch,M.D.,
19
Barry J Make,
20
Fernando J. Martinez,
M.D., M.S.,
21
Joe W. Ramsdell, M.D.,
3
Rishindra Reddy, M.D.,
22
Brian D. Ross, Ph.D.,
13
Harry
B. Rossiter, Ph.D.,
8
Robert M. Steiner, M.D.,
23
Matthew J. Strand, Ph.D.,
11,12
Edwin J.R. van
Beek, M.D., Ph.D.,
24
Emily S. Wan, M.D.,
25
George R. Washko, M.D.,
10
J. Michael Wells,
M.D.,
1,2
Chris H. Wendt,M.D.,
26
Robert A. Wise, M.D.,
27
Edwin K. Silverman, M.D., Ph.D.,
25
James D. Crapo, M.D.,
20
*Russell P. Bowler, M.D.,Ph.D.,
20
*MeiLan K. Han, M.D., M.S.
21
for
the COPDGene Investigators.
1
Division of Pulmonary, Allergy and Critical Care Medicine, University of Alabama at
Birmingham, Birmingham, AL 35294;
2
UAB Lung Health Center, University of Alabama at
Birmingham, Birmingham, AL 35294;
3
Division of Pulmonary, Critical Care and Sleep
Medicine, University of California San Diego, San Diego, CA 92093;
4
School of Public Health,
University of Michigan, Ann Arbor, MI 48109;
5
Division of Pulmonary and Critical Care
Medicine, University of Texas Health Science Center at San Antonio, and South Texas Veterans
Health Care System, San Antonio, TX 78229;
6
Department of Epidemiology, School of Public
Health, Johns Hopkins University, Baltimore, MD 21205;
7
Pulmonary, Critical Care and Sleep
Medicine, Baylor College of Medicine, Houston, TX 77030;
8
Division of Pulmonary and Critical
Care Physiology and Medicine, and Rehabilitation Clinical Trials Center Los Angeles
Biomedical Research Institute at Harbor-UCLA Medical Center, Torrance, CA 90502;
9
Pulmonary and Critical Care Medicine, Temple University Hospital, Philadelphia, PA 19140;
10
Division of Pulmonary and Critical Care Medicine, Brigham and Women's Hospital, Boston,
MA 02115;
11
Department of Biostatistics and Bioinformatics, National Jewish Health, Denver,
CO 80206;
12
Department of Biostatistics and Informatics, Colorado School of Public Health,
University of Colorado Denver, Denver, CO 80045;
13
Department of Radiology, Center for
Molecular Imaging, University of Michigan, Ann Arbor, MI 48109;
14
Departments of Radiology,
Medicine and Biomedical Engineering, University of Iowa, Iowa City, IA 52242;
15
Department
of Pathology and Laboratory Medicine, University of British Columbia, and James Hogg
Research Centre, St. Paul's Hospital, Vancouver, BC V6Z 1Y6, Canada;
16
Department of
Radiology, University of Michigan, Ann Arbor, MI 48109;
17
Department of Epidemiology,
Colorado School of Public Health, University of Colorado Denver, Denver, CO 80045;
18
Department of Pathology, University of Michigan, MI 48109;
19
Department of Radiology,
National Jewish Health, Denver, CO 80206;
20
Division of Pulmonary, Critical Care and Sleep
Medicine, National Jewish Health, Denver, CO 80206;
21
Division of Pulmonary & Critical Care
2Medicine, University of Michigan, Ann Arbor, MI 48109;
22
Division of Thoracic Surgery,
University of Michigan, Ann Arbor, MI 48109;
23
Department of Radiology, Temple University
Hospital, Philadelphia, PA 19140;
24
Clinical Research Imaging Centre, University of Edinburgh,
Edinburgh, UK;
25
Channing Division of Network Medicine, Brigham and Women's Hospital,
Harvard Medical School, Boston, MA 02115;
26
Minneapolis VAMC, Pulmonary, Allergy,
Critical Care and Sleep Medicine Section, University of Minnesota, Minneapolis, MN 55417;
27
Division of Pulmonary and Critical Care Medicine, Johns Hopkins University School of
Medicine, Baltimore, MD 21224
Į
Co-first authors
*Co-senior authors
Corresponding author: MeiLan K. Han, M.D., University of Michigan, Division of Pulmonary
and Critical Care Medicine, Ann Arbor, MI 48109. Email: mrking@med.umich.edu. Phone: 734-
936-5201. Fax: 734-936-5208
Running Title: Functional small airways disease and FEV1 decline in COPD
Descriptor: 8.17
Clinical Trial Registration: ClinicalTrials.gov NCT00608764
Author Contributions: Dr. Han had full access to all of the data in the study, takes
responsibility for the integrity of the data and the accuracy of the data analysis, had authority
over manuscript preparation and the decision to submit the manuscript for publication.
Study concept and design: Bhatt, Soler, Bowler and Han
Acquisition, analysis, or interpretation of data: All authors
Drafting of the manuscript: Bhatt, Soler, Bowler and Han
Critical revision of the manuscript for important intellectual content: All authors
Statistical analysis: Xin, Murray, Bhatt and Han
Obtained funding: Crapo and Silverman
Study supervision: All authors
Funding Source:
The project was supported by Award R01 HL089897, R01 HL089856, R01 HL122438 and R44
HL118837 from the National Heart, Lung and Blood Institute. The COPDGene project is also
supported by the COPD Foundation through contributions made to an Industry Advisory Board
comprised of AstraZeneca, Boehringer Ingelheim, Novartis, Pfizer, Siemens, Sunovion and
GlaxoSmithKline.
Manuscript Word Count: 3009
3At a Glance Commentary:
Scientific Knowledge on the Subject
Airflow obstruction is influenced by both small airways disease and emphysema. The small
conducting airways are the major site of airflow obstruction in chronic obstructive pulmonary
disease (COPD), and histologic data suggest small airway abnormality may precede emphysema.
The impact of these components of COPD on lung function decline remains unknown.
What This Study Adds to the Field
In a population of current and former smokers, we demonstrate that the rate of FEV1 decline is
greatest in mild COPD. A novel, CT biomarker demonstrates functional small airways disease
contributes to lung function decline particularly in mild disease, even amongst individuals
without airflow obstruction.
4Abstract
Background: The small conducting airways are the major site of airflow obstruction in COPD
and may precede emphysema development. We hypothesized a novel CT biomarker of small
airways disease predicts FEV1 decline.
Methods: We analyzed 1,508 current and former smokers from COPDGene with linear
regression to assess predictors of change in FEV1 (ml/year) over 5 years. Separate models for
non-obstructed and obstructed subjects were generated using baseline clinical and physiologic
predictors in addition to two novel CT metrics created by Parametric Response Mapping (PRM),
a technique pairing inspiratory and expiratory CT images to define emphysema (PRM
emph
) and
functional small airways disease (PRM
fSAD
), a measure of non-emphysematous air trapping.
Results: Mean (SD) rate of FEV1 decline in ml/year for GOLD 0-4 was as follows: 41.8 (47.7),
53.8 (57.1), 45.6 (61.1), 31.6 (43.6), and 5.1 (35.8) respectively (trend test for grades 1-4,
p<0.001). In multivariable linear regression, for non-obstructed participants, PRM
fSAD
but not
PRM
emph
was associated with FEV1 decline, p<0.001. In GOLD 1-4 participants, both functional
small airways disease (PRM
fSAD
) and emphysema (PRM
emph
) were associated with FEV1 decline
(p<0.001 and p=0.001, respectively). Based on the model, the proportional contribution of the
two CT metrics to FEV1 decline, relative to each other, was 87% vs. 13% and 68% vs. 32% for
PRM
fSAD
and PRM
emph
in GOLD 1/2 and 3/4, respectively.
Conclusions: Both CT assessed functional small airways disease and emphysema are
associated with FEV1 decline, but the association with functional small airways disease has
greatest importance in mild-to-moderate stage COPD where the rate of FEV1 decline is the
greatest.
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6Introduction
Cigarette smoking is associated with an accelerated decline in the forced expiratory
volume in 1 second (FEV1), resulting in airflow obstruction in a significant proportion of
smokers.(1) FEV1 is influenced by both airway resistance and reduced elastic recoil due to
emphysema.(2) The small conducting airways <2 mm in diameter that offer little resistance to
airflow in normal lungs become the major site of airflow obstruction in persons with chronic
obstructive pulmonary disease (COPD), (3, 4) representing a “silent zone” within the lung where
obstructive airway disease can accumulate without being noticed.(3-5) In fact, histologic and
micro CT data from explanted lung tissue suggest that widespread narrowing and destruction of
the smaller airways actually occurs before emphysematous lesions become large enough to be
visible on standard CT imaging.(6) Unfortunately, the resolution of current clinical CT imaging
prevents direct visualization of small airways disease beyond the subsegmental bronchi.
While small airways disease can be assessed by “gas trapping”, defined as the percent of
voxels < -856 Hounsfield Units (HU) on expiratory CT, a significant limitation of this approach
is that many lung regions that trap gas on exhalation will also show emphysematous destruction
when fully inflated to total lung capacity (TLC).(7) A recently developed CT analytic method,
Parametric Response Mapping (PRM), matches inspiratory and expiratory images on a voxel-by-
voxel basis to examine the change in density between inspiratory and expiratory images.(8) By
applying separate density thresholds to the inspiratory and expiratory voxel measurements, we
are able to discriminate emphysema (PRM
emph
) from non-emphysematous air trapping, termed
functional small airways disease (PRM
fSAD
), see Figure 1 and Supplemental Figure E1.
While emphysema defined as the percent of voxels <-950 HU on inspiratory CT has
previously been associated with lung function decline, the relative contribution of CT defined
7small airways disease has not been examined.(9) Here we present an analysis of a large
multicenter study of current and former smokers to understand the relative contribution of small
airways disease and emphysema to subsequent lung function decline across the disease severity
spectrum over a five year period of observation. Some of the results in this manuscript have
been previously reported in the form of an abstract. (10)
Methods
Study population and assessments
Subjects participating in the follow-up phase of COPDGene (Genetic Epidemiology of
COPD), a large multicenter longitudinal observational cohort study were included in this
analysis. Written informed consent was obtained from each subject and the study was approved
by the institutional review boards of all 21 participating centers. Current and former smokers
ZLWKSDFN\HDU VPRNLQJKLVWRU\ZLWK DQG ZLWKRXW DLUIORZREVWUXFWLRQZHUH HQUROOHG
Inclusion criteria also included non-Hispanic White or African American race; exclusion criteria
included a history of other lung disease except asthma, prior surgical excision involving a lung
lobe or greater, active cancer, metal in the chest and history of chest radiation therapy. The
original COPDGene cohort enrolled 10,192 individuals. 1,508 GOLD 0-4 subjects who had
completed a second COPDGene visit approximately 5 years after the first visit with acceptable
pulmonary function and CT scans from visit 1 and 2 by November 2014 were included for this
analysis (see Supplemental Figure E2, Consort Diagram).
At both visits, spirometry was performed before and after administration of 180 mcg of
albuterol (ndd Easy-One spirometer, Andover, MA). Bronchodilator reversibility was defined as
at least 12% and 200 ml increase in FEV1 and/or forced vital capacity (FVC)
8postbronchodilator.(12); post bronchodilator values were used for analyses.(12) COPD was
defined by post-bronchodilator FEV1/FVC < 0.70 at baseline visit per the Global Initiative for
Chronic Obstructive Lung Disease (GOLD) guidelines.(13) Disease severity was defined by
GOLD grade. “GOLD 0” was defined as by post-bronchodilator FEV1)9&DWEDVHOLQH
visit and FEV1 SUHGLFWHG   3DUWLFLSDQWV ZLWK )(91/FVC>0.70 but with FEV1 <80%
predicted were deemed to have Preserved Ratio Impaired Spirometry (PRISm) and were not
included in the analyses.(14)
Data on demographics, smoking burden, respiratory morbidity, exacerbations and
comorbidities used in this analysis were recorded at the baseline visit. Respiratory disease related
health impairment and quality of life was assessed using the St George’s Respiratory
Questionnaire (SGRQ),(15) and dyspnea using the Modified Medical Research Council
(MMRC) dyspnea score.(16) History of exacerbations in the previous year was obtained at the
time of initial visit, with exacerbations defined as acute worsening of respiratory symptoms that
required use of either antibiotics or systemic steroids.(13)
At the baseline visit, paired inspiratory and expiratory scans were obtained at maximal
inspiration (total lung capacity, TLC) and end-tidal expiration (functional residual capacity,
FRC).(11) Emphysema was quantitated using the percentage of low attenuation units <-950 HU
at TLC, and gas trapping using the percentage of low attenuation units <-856 HU at end-
expiration using Slicer software (www.Slicer.org).(17) Using funds from NHLBI Grant # R01
HL122438, PRM analysis was also performed on paired registered inspiratory and expiratory
images to distinguish functional small airways disease (PRM
fSAD
) from emphysema (PRM
emph
)
by Imbio LLC, Minneapolis, MN, USA using Lung Density Analysis
TM
software.(8) Briefly,
PRM
fSAD
was defined as areas of lung that are >-950 HU on inspiration but also <-856 HU on
9expiration. PRM
emph
was defined as areas of lung that are <-950 HU on inspiration and <-856
HU on expiration. (See Supplemental Figure E1).
Statistical analyses
All statistical analyses were performed in SAS 9.3 (Cary, NC). Comparisons were
performed using two-sample t-tests for continuous variables and chi-squared statistics for
categorical variables. Linear regression was used to study univariate and multivariable
associations between potential predictors and change in FEV1 (ml/year). The outcome of
change in FEV1 for each individual was calculated by subtracting visit 1 FEV1 from visit 2 FEV1
and dividing by the time between visits to calculate change in ml/year. In addition to PRM CT
metrics which were the covariates of interest, age, sex, race, height, smoking history and scanner
type were included as covariates in all multivariable regression models regardless of univariate
statistical significance. Otherwise, only parameters associated with FEV1 change at a
significance level of p<0.05 were retained in the multivariable model. Linear regression
analyses were repeated separately for GOLD 0 participants and also for GOLD 1-4 participants.
Among GOLD 1-4 participants, the contribution to FEV1 decline for each CT metric was
calculated by multiplying the parameter estimate from the multivariate model by the mean CT
metric value for the corresponding disease stage and dividing that value by the sum of this
product for both metrics (PRM
fSAD
and PRM
emph
). P<0.05 was considered statistically significant
for all analyses.
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Results
Subject characteristics
Results for 1,508 participants with complete data needed for multivariable regression
analyses are reported here (Consort Diagram, Supplemental Figure E2). Baseline demographics
and lung function are reported in Table 1, categorized by severity of airflow obstruction
according to GOLD grade. Imaging metrics show an increase in emphysema with increasing
GOLD spirometry grade as measured by both density analysis (Emphysema) and PRM
(PRM
emph
) and an increase in small airways disease (PRM
fSAD
) as well.
FEV1 change over time
The median follow-up time for the entire cohort was 64 months (range 49 to 79) with a
mean (SD) rate of decline in FEV1 of 41.1 (52.0) ml/year (Figure 2). For GOLD 0 participants,
mean rate of FEV1 decline was 41.8 (47.7) ml/year. Those with GOLD grade 1 had the most
rapid rate of decline 53.8 (57.1) ml/year, with progressively slower rates of decline with
increasing GOLD grades: 45.6 (61.1), 31.6 (43.6), and 5.1 (35.8) for GOLD grades 2 to 4
respectively (trend test for grades 1-4, p<0.001). Supplemental Figure E3 demonstrates that
FEV1 decline expressed as change in percent predicted follows similar trend to FEV1 change in
ml.
Clinical Predictors of FEV1 change
The rate of FEV1 change was strongly associated with a number of baseline demographic
variables. Univariate and multivariable analyses for FEV1 decline are presented in Supplemental
Tables E1 and E2. In multivariable analysis, FEV1 decline (ml/year) was greater in current
11
versus former smokers (6.91 ml/year greater decline; 95% CI 0.82, 13.01; p=0.01). Those with
baseline bronchodilator reversibility had greater FEV1 decline compared to those without
bronchodilator reversibility (18.80 ml/year greater decline; 95% CI 12.60, 25.01; p<0.001).
Greater rates of FEV1 decline were also seen with higher baseline FEV1 (14.45 ml/year decline
per L; 95% CI 6.75, 22.14; p<0001), higher baseline FVC (14.74 ml/year decline per L; 95% CI
8.15, 21.32; p<0.001) and more smoking pack years (1.43 ml/year decline per 10 pack-years;
95% CI 0.82, 2.57; p=0.01). Exacerbations in the prior year demonstrated no significant
association with FEV1 decline in either the univariate (p=0.38) or multivariable model (p=0.55)
and therefore was not retained in the final model. African American race was associated with
more rapid decline compared to Non-Hispanic White participants (11.30 ml/year greater decline;
95% CI 4.34, 18.25; p=0.002) in multivariable analysis. Female sex was associated with more
rapid FEV1 decline than males (8.39 ml/year greater decline; 95% CI 0.94, 15.84; p=0.03), our
analysis was not designed to assess sex difference.
Quantitative imaging and FEV1 change
Results for the overall model are in Table E2. For all subjects, both PRM
fSAD
and
PRM
emph
had a statistically significant association with lung function decline. In order to
understand the impact of CT assessment of small airways disease and emphysema on FEV1
decline based on presence or absence of baseline airflow obstruction, we also performed separate
linear regression models for GOLD 0 and GOLD 1-4 subjects. Parameter estimates for the CT
metrics for these stratified models are presented in Table 2.
Amongst GOLD 0 participants, PRM
fSAD
but not PRM
emph
was significantly associated
with FEV1 decline. For every additional 5% of lung affected by PRM
fSAD
, a significant decline
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in FEV1 was seen (2.2 ml/year per 5% PRM
fSAD
; p=0.04). Amongst GOLD 1-4 participants, for
every additional 5% of lung affected by PRM
fSAD
or PRM
emph
a significant decline in FEV1 was
seen: (4.5 ml/year; 95% CI 6.3, 2.6; p<0.001 and 3.5 ml/year; 95% CI 5.6, 1.4; p=0.001,
respectively).
We also sought to understand the contribution of CT metrics to FEV1 decline relative to
each other in milder versus more severe disease (Supplemental Figure E4). We therefore used
the parameter estimates from the linear regression model and mean CT metric values
corresponding to GOLD 1-2 and GOLD 3-4 groups to determine the relative contribution of
PRM
fSAD
and PRM
emph
to FEV1 decline. PRM
fSAD
was associated with significantly greater
FEV1 decline than PRM
emph
for both groups (p=0.001 for GOLD1-2; p=0.007 for GOLD 3-4),
although this was even more pronounced for the GOLD 1-2 group (87% vs. 13% and 68% vs.
32% for PRM
fSAD
and PRM
emph
in GOLD 1-2 and 3-4, respectively).
Finally, in order to better understand the significance of PRM
fSAD
in the GOLD 0 group,
we also examined the mean rate of decline for varying levels of PRM
fSAD
. As previously stated,
the mean change in FEV1 for GOLD 0 group was 41.8 (47.7) ml/year. For individuals at or
above the median PRM
fSAD
level for the GOLD 0 group (PRM
fSAD
11%), the mean decline in
FEV1 was 45.2 (47.8) ml/year vs. 38.6 (47.2) ml/year for those below the median (p=0.05). For
individuals at or above the 75
th
percentile of PRM
fSAD
for GOLD 0 group (PRM
fSAD
16%) the
mean decline in FEV1 was 49.2 (50.2) ml/year compared to those below the 75
th
percentile, 39.0
(46.4), p= 0.009. Supplemental Table E3 shows mean FEV1 decline across quartiles of PRM
fsad
for GOLD 0.
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Discussion
We demonstrated that, in a cohort of current and former smokers, functional small
airways disease as measured by chest CT is associated with subsequent FEV1 decline. While we
showed that emphysema is also associated with FEV1 decline, its impact relative to small airway
abnormality is weaker, particularly in mild-to-moderate disease stage. Finally we demonstrated
that this association between functional small airways disease and FEV1 decline is evident in
GOLD 0 subjects even before the development of spirometrically detected airflow obstruction.
Our findings support prior pathologic investigations of COPD. The small airways < 2
mm in diameter are the major site of increased airflow resistance in COPD as established first in
the 1960s through retrograde catheter studies in post-mortem lungs(3) and then later in living
lungs.(4) Peripheral airway inflammation has been noted in young smokers even before COPD
is established.(18) Further increases in this inflammatory response along with development of
airway wall structural abnormalities have also been described in established COPD resulting in
airway lumen narrowing.(6) Recent histologic and micro CT data also reveal that narrowing and
disappearance of terminal bronchioles precedes the development of emphysema.(6)
Previously it has been demonstrated in individuals with moderate to severe COPD that
emphysema on CT, defined as the percentage of voxels with density <-950 HU at full
inspiration, is associated with a more rapid decline of FEV1.(9, 19) However, a good way to
assess the small airways in patients radiographically has been lacking. Gas trapping, measured
as the percent of voxels <-856 HU using expiratory images alone, is limited by the inability to
distinguish small airways disease from emphysema.(7) Unlike standard densitometric analyses
using inspiratory or expiratory images in isolation, PRM digitally co-registers inspiratory and
expiratory CT images which should help distinguish small airways disease from emphysema.(8)
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Here we demonstrated, in a large cohort of current and former smokers with a broad
spectrum of disease severity, that functional small airways disease on CT as measured by PRM is
significantly associated with decline in FEV1 particularly in mild-to-moderate stage disease,
whereas the contributions of small airways disease and emphysema are relatively more equal in
later stages (GOLD 3-4). This association between functional small airways disease and FEV1
decline was evident even before the development of spirometrically detected airflow obstruction.
We do note, however, that the effect size for PRM
fSAD
was attenuated in GOLD 0 individuals as
compared to those with established airflow obstruction. We postulate that airway disease if
present in non-obstructed smokers may still be of a reversible nature and may represent
bronchospasm or inflammation as opposed to fibrosis or airway loss. In prior work comparing
paired CT scans in smokers with GOLD 0-4 disease performed at 30 days and one year apart, we
demonstrated particularly in individuals with mild-to-moderate stage disease that PRM
fSAD
may
increase or decrease over these shorter time intervals suggesting a reversible component.(20)
Here we demonstrated that in those with established airflow obstruction, PRM
fSAD
is strongly
associated with FEV1 decline. While PRM
emph
was also associated with FEV1 decline, it’s
relative impact was weaker, particularly in mild-to-moderate disease. This is not to say,
however, that emphysema as defined by PRM in mild-to-moderate stage disease is not important
when present, but it is generally lesser in magnitude than small airways disease. We also
demonstrated that high levels of CT defined small airway abnormality were present in
individuals without airflow obstruction who subsequently experience more rapid declines in
FEV1. In fact, the rate of decline experienced by GOLD 0 participants with PRM
fSAD
> median
value (45.2 ml/year) was comparable to the rate of decline experienced by GOLD 2 individuals
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(45.6 ml/year). These findings have potential implications for identifying individuals without
airflow obstruction but at high risk for more rapid lung function decline.
Our study has several potential limitations. We had only two measurements of lung
function separated by a median of approximately 5 years. However, within-person variability in
our results was offset by the large number of individuals used to estimate average change. We
also did not have data on lifelong FEV1 trajectories;(21) however, our goal was primarily to
examine the relative impact of structural lung disease on subsequent FEV1 decline. Our analysis
was based on subjects who had completed their second study visit by November 3, 2014. It is
possible that patients who were first to follow-up differ from those who were either late for their
second visit or lost to follow-up. Many of the patients with airflow obstruction were receiving
therapy for their disease. Although no existing pharmacotherapy has been conclusively shown to
affect the rate of FEV1 decline, this still may have influenced our results. However, we chose
not to include pharmacotherapy data in these analyses in order to reduce biases inherent to
patient-reported pharmaco-epidemiologic data. (22) We also describe an imaging metric that
measures “functional” small airways disease through the change in lung density seen between
inspiration and expiration. It is not a direct measure of airway thickness or destruction. The lack
of a normal increase in lung density between inspiration and expiration implies that air is
trapped. We postulate that such air trapping is due to small airways disease, but the exact
contribution of larger visible and smaller non-visible airways is actively being investigated with
radiologic-pathologic correlation. In addition, this algorithm assigns every voxel to a specific
disease category which likely represents the majority of abnormality, but in reality there may be
a mix of histologic abnormalities in the tissue covered by one voxel. The goal for the expiratory
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images was to obtain images at functional residual capacity. It is possible that this
underestimates the amount of air trapping that might be seen at residual volume.
The current study also has a number of strengths. PRM is an advance over the traditional
“gas trapping” metric defined by voxels <-856 HU on expiration which likely combines true
emphysema and small airway abnormality.(7) Here we allow the relative contribution from each
to be resolved. Analyses were performed within a well-characterized cohort that included
subjects with all stages of disease severity represented proportionally and with stringent
spirometry and CT quality control. PRM metrics provide a novel noninvasive CT biomarker for
disease progression, particularly in mild to moderate COPD. Even though there are no
established therapies to treat lung function decline, early identification of these subjects will
allow prognostication and perhaps targeting novel therapies in these individuals using the
detailed spatial information provided on disease distribution and relative contribution of small
airways disease and emphysema.
Conclusions
Both CT assessed functional small airways disease and emphysema are associated with
FEV1 decline, but the association with functional small airways disease has greatest importance
in mild-to-moderate stage COPD where the rate of FEV1 decline is the greatest. These findings
are consistent with prior pathologic studies and allow a non-invasive means to target at-risk
patients at milder stages of the disease.
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Table 1. Baseline demographics
n=1,508 GOLD Spirometry Grade
0
n=751
1
n=150
2
n=356
3
n=192
4
n=59
Age (years) 58.2 (8.6) 63.8 (8.1) 63.3 (8.4) 64.1 (7.9) 62.8 (7.6)
Sex, n (% Female) 395 (52.6) 66 (44.0) 161 (45.2) 87 (45.3) 29 (49.2)
Race, n (% African American) 245 (32.6) 28 (18.7) 79 (22.2) 36 (18.8) 5 (8.5)
Height (cm) 169.5 (9.2) 169.7 (10.1) 170.9 (9.3) 169.9 (10.3) 169.6 (9.0)
FEV1 (L) 2.8 (0.7) 2.6 (0.7) 1.9 (0.5) 1.2 (0.3) 0.68 (0.2)
FEV1 % predicted 97.7 (11.4) 91.6 (8.6) 65.0 (8.3) 40.9 (5.9) 23.6 (4.1)
FVC (L) 3.6 (0.9) 4.1 (1.0) 3.3 (0.9) 2.7 (0.8) 2.3 (0.6)
FVC % predicted 96.2 (11.3) 108.5 (11.2) 87.4 (13.4) 72.4 (12.8) 59.1 (11.6)
FEV1/FVC 0.79 (0.1) 0.64 (0.04) 0.47 (0.08) 0.44 (0.09) 0.31 (0.05)
Smoking pack years 37.2 (20.0) 40.0 (49.2) 37.9 (48.6) 55.4 (24.8) 57.8 (28.6)
Current smokers, n (%) 364 (48.5) 60 (40.0) 135 (37.9) 60 (31.3) 10 (16.9)
*Bronchodilator reversibility, n (%) 68 (9.1) 42 (28.0) 136 (38.2) 80 (41.7) 19 (32.2)
Exacerbations in the prior year 0.13 (0.49) 0.13 (0.37) 0.43 (0.95) 0.71 (1.15) 1.14 (1.50)
Follow-up time (months) 63.9 (4.5) 63.7 (4.2) 64.1 (4.2) 64.0 (4.1) 65.0 (5.1)
Emphysema (%LAA<-950HUinsp) 2.7 (3.0) 6.9 (6.4) 8.4 (8.4) 17.9 (12.6) 26.6 (13.6)
Gas Trapping (%LAA<-856HUexp) 11.8 (9.9) 23.4 (12.1) 29.9 (15.4) 48.7 (16.3) 60.9 (12.2)
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All values expressed as mean (SD) except categorical variables expressed as n (%). SD = standard deviation. GOLD = Global Initiative for Chronic Obstructive Lung
Disease. FEV1 = Forced expiratory volume in the first second. FVC = Forced vital capacity. LAA<-950HUinsp = Low attenuation areas <-950 Hounsfield Units at end
inspiration. LAA<-856HUexp = Low attenuation areas <-856 Hounsfield Units at end expiration. PRM = Parametric response mapping.
*Bronchodilator reversibility defined as 12% and 200 ml increase in FEV1 and/or FVC
PRM functional small airways disease (%) 12.4 (9.7) 22.2 (10.7) 26.6 (11.6) 36.3 (10.0) 39.2 (9.9)
PRM emphysema (%) 0.6 (1.4) 3.3 (4.4) 5.6 (7.4) 15.2 (12.9) 24.7 (14.7)
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Table 2. Association between PRM emphysema and fSAD on change in FEV1 ml/year by
baseline GOLD grade (Estimate, 95% CI, p-value). Two separate models are shown in rows for the
following groups (1) GOLD 0 and (2) GOLD 1-4 subjects. Parameter estimates and mean values for
respective CT metrics are shown. All models adjusted for potential confounders as outlined below*.
PRM
fSAD
PRM
emph
GOLD 0, n=751
Parameter estimate per 5% (ml/yr) -2.2 (95% CI -4.2, -0.1) p=0.04 5.5 (95% CI -8.0, 19.1) p=0.42
Mean value CT metric (%) 12.4 (9.7) 0.6 (1.4)
GOLD 1 – 4, n=757
Parameter estimate per 5% (ml/yr) -4.5 (95% CI -6.3, -2.6) p<0.001 -3.5 (95% CI -5.6, -1.4) p=0.001
Mean value CT metric (%) 29.2 (12.3) 9.1 (11.4)
PRM = Parametric response mapping. fSAD = functional small airways disease. GOLD = GOLD = Global Initiative for
Chronic Obstructive Lung Disease. PRM
emph
= emphysema on parametric response mapping. PRM
fSAD
= functional small
airways disease on parametric response mapping.
*All models adjusted for age, race, sex, height, current smoking, smoking history in pack years, baseline FEV1, baseline
FVC , bronchodilator reversibility and scanner type.
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Figure 1: Graphic representation of the Parametric Response Mapping (PRM) methodology.
COPD of GOLD grades 1-4 are shown in rows. In columns, inspiratory and expiratory CT images are
shown on the left. PRM emphysema voxels in red and PRM functional small airways voxels in yellow
are shown on the right. While every voxel receives an individual categorical assignment, in this
example PRM
Emph
and PRM
fSAD
are distributed throughout the lung. Greater intensity of color
indicates more voxels classified in each category.
PRM = Parametric response mapping. PRM
emph
= emphysema on parametric response mapping. PRM
fSAD
= functional small
airways disease on parametric response mapping. PRM
norm
= neither emphysema nor functional airways disease on
parametric response mapping. GOLD = Global Initiative for Chronic Obstructive Lung Disease.
Figure 2. Change in FEV1 (ml/year) between Visit 1 and Visit 2 by disease stage. Figures show the
proportion of subjects in each disease stage group with varying levels of change in FEV1 (ml/year)
over a 5-year period for (A) Global Initiative for Obstructive Lung Disease (GOLD) 0, mean -41.8
(47.7) ml/yr; (B) GOLD grades 1 and 2 combined, mean -48.0 (SD 60.0) ml/yr; and (C) GOLD grades
3 and 4 combined, mean -25.3 (SD 43.3) ml/yr.
FEV1 = Forced Expiratory Volume in 1 second. GOLD = GOLD = Global Initiative for Chronic Obstructive Lung Disease.
Xcvlk;
PRM Normal (%) PRM Functional small
airways disease (%)
PRM Emphysema (%)
GOLD 1 78.8 18.5 0.8
GOLD 2 44.9 41.6 7.0
GOLD 3 28.8 40.8 25.1
GOLD 4 21.8 26.9 43.2


1Supplemental Table E1. Univariate Analyses for predictors of FEV1 decline in ml/year
(n=1,508). Negative values indicate decrease in FEV1 at Visit 2.
Parameter
Estimate
95% Confidence
Interval
P-value
Age (per 10 years) 3.35 0.37, 6.33 0.03
Gender (female) 15.28 10.08, 20.47 <0.001
Race (African American) -3.12 -9.09, 2.86 0.31
Height (cm) -0.75 -1.01, -0.49 <0.001
Baseline FEV1 (ml) -12.38 -15.22, -9.54 <0.001
Baseline FVC (ml) -15.17 -18.52, -13.52 <0.001
Smoking pack years (per 10 years) -1.59 -2.68, -0.50 0.004
Current smoking -7.96 -13.27, -2.65 0.003
Bronchodilator reversibility -15.75 -21.94, -9.95 <0.001
Exacerbations in the prior year 1.43 -1.79, 4.66 0.38
PRM emphysema (per 5%) 0.26 -1.18, 1.69 0.72
PRM small airways disease (per 5%) -0.82 -1.77, 0.12 0.09
% Emphysema (per 5%) -0.31 -1.68, 1.05 0.65
% Gas trapping (per 5%) -0.32 -1.00, 0.36 0.36
FEV1 = Forced expiratory volume in the first second. FVC = Forced vital capacity. PRM = Parametric response
mapping.
2Supplemental Table E2. Multivariable linear regression on FEV1 decline in ml/year.
Negative values indicate decline in FEV1 at Visit 2 compared to Visit 1, n=1508.
Parameter
Estimate
95% Confidence
Interval
P-value
Age (per 10 years) -2.64 -6.31, 1.03 0.16
Gender (female) -8.39 -15.84, -0.94 0.03
Race (African American) -11.30 -18.25, -4.34 0.002
Height (per cm) 0.62 0.21, 1.03 0.003
Baseline FEV1 (per ml) -14.45 -22.14, -6.75 <0.001
Baseline FVC (per ml) -14.74 -21.32, -8.15 <0.001
Smoking pack years (per 10 years) -1.43 -2.57, -0.30 0.01
Current smoking -6.91 -13.01, -0.82 0.03
Bronchodilator reversibility -18.80 -25.01, -12.60 <0.001
PRM small airways disease (per 5%) -2.78 -4.05, -1.52 <0.001
PRM emphysema (per 5%) -2.52 -4.35, -0.70 0.007
*additionally adjusted for scanner type
FEV1 = Forced expiratory volume in the first second. FVC = Forced vital capacity. PRM = Parametric response
mapping.
3Supplemental Table E3: FEV1 decline in GOLD 0 subjects stratified by PRM
fSAD
quartiles
PRM
fSAD
quartile 1
<5%
PRM
fSAD
quartile 2
5-10%
PRM
fSAD
quartile 3
11-15%
PRM
fSAD
quartile 4

FEV1 decline (ml/yr) 35.4 (47.3) 40.5 (47.3) 40.3 (44.5) 49.2 (50.2)
FEV1 = Forced expiratory volume in the first second. PRM
fSAD
= functional small airways disease defined using
parametric response mapping.
4Supplemental Figure E1. Parametric Response Mapping Methodology. (1) Inspiratory and
expiratory CT images are acquired; (2) image processing allows the two images to be spatially
aligned and voxels matched between the two images; (3) joint registration allows voxels to be
classified as “normal” lung, “functional small airways disease” or fSAD and “emphysema”
based on Hounsfield Unit measures of density on both the inspiratory and expiratory images.
Supplemental Figure E2: Consort Diagram.
Supplemental Figure E3. FEV1 decline expressed as percent change by disease stage.
PRM = Parametric response mapping. GOLD = Global Initiative for Chronic Obstructive Lung Disease.
PRMemph = emphysema defined using parametric response mapping. PRMfSAD= functional small
airways disease defined using parametric response mapping. GOLD = Global Initiative for Obstructive
Lung Disease.
Supplemental Figure E4: Distribution of PRM
fSAD
and PRM
emph
by disease stage.
PRM = Parametric response mapping. GOLD = Global Initiative for Chronic Obstructive Lung Disease.
PRM
emph
= emphysema defined using parametric response mapping. PRM
fSAD
= functional small
airways disease defined using parametric response mapping.

Supplemental Figure E2. Consort Diagram 
 
                                                                           
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CT = Computed Tomography. PRM = Parametric Response Mapping. 
1,775 Gold 0-4 subjects 
with complete 
demographic and 
spirometric data as of 
November 3, 2014 
1,517 subjects with 
acceptable inspiratory and 
expiratory CT scans and 
PRM data 
9 subjects missing bronchodilator responsiveness data 
258 subjects with quality control errors precluding use of 
the CT data 
1,508 subjects with 
acceptable inspiratory and 
expiratory CT scans 


